These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 9815897)

  • 1. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
    Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
    BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic value of the soluble urokinase-type plasminogen activator receptor (s-uPAR) in plasma of breast cancer patients with and without metastatic disease.
    Nijziel MR; Van Oerle R; Hellenbrand D; Van Pampus EC; Hillen HF; Hamulyák K
    J Thromb Haemost; 2003 May; 1(5):982-6. PubMed ID: 12871365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
    Nakatsuka E; Sawada K; Nakamura K; Yoshimura A; Kinose Y; Kodama M; Hashimoto K; Mabuchi S; Makino H; Morii E; Yamaguchi Y; Yanase T; Itai A; Morishige KI; Kimura T
    Oncotarget; 2017 Oct; 8(52):89887-89902. PubMed ID: 29163796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum uPAR as Biomarker in Breast Cancer Recurrence: A Mathematical Model.
    Hao W; Friedman A
    PLoS One; 2016; 11(4):e0153508. PubMed ID: 27078836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The consumption of seaweed as a protective factor in the etiology of breast cancer: proof of principle.
    Teas J; Vena S; Cone DL; Irhimeh M
    J Appl Phycol; 2013 Jun; 25(3):771-779. PubMed ID: 23678231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NFκB-Mediated Mechanisms Drive PEDF Expression and Function in Pre- and Post-Menopausal Oestrogen Levels in Breast Cancer.
    Brook N; Gill J; Dharmarajan A; Chan A; Dass CR
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature.
    Cao M; Shi E; Wang H; Mao L; Wu Q; Li X; Liang Y; Yang X; Wang Y; Li C
    Int J Nanomedicine; 2022; 17():4293-4306. PubMed ID: 36134201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
    Kumar AA; Buckley BJ; Ranson M
    Biomolecules; 2022 Jan; 12(2):. PubMed ID: 35204653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications.
    Li Santi A; Napolitano F; Montuori N; Ragno P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer.
    Stroomberg HV; Kristensen G; Drimer Berg K; Lippert S; Brasso K; Røder MA
    Diagnostics (Basel); 2020 Oct; 10(11):. PubMed ID: 33126666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
    Kubala MH; DeClerck YA
    Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.
    de Geus SW; Baart VM; Boonstra MC; Kuppen PJ; Prevoo HA; Mazar AP; Bonsing BA; Morreau H; van de Velde CJ; Vahrmeijer AL; Sier CF
    Biomark Insights; 2017; 12():1177271917715443. PubMed ID: 28690396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
    Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A
    Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo anti-metastatic effects of uPAR retargeted measles virus in syngeneic and xenograft models of mammary cancer.
    Jing Y; Bejarano MT; Zaias J; Merchan JR
    Breast Cancer Res Treat; 2015 Jan; 149(1):99-108. PubMed ID: 25519042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.
    Boonstra MC; Verbeek FP; Mazar AP; Prevoo HA; Kuppen PJ; van de Velde CJ; Vahrmeijer AL; Sier CF
    BMC Cancer; 2014 Apr; 14():269. PubMed ID: 24742002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High concentration of urokinase-type plasminogen activator receptor in the serum of women with primary breast cancer.
    Thielemann A; Baszczuk A; Kopczyński P; Kopczyński Z
    Contemp Oncol (Pozn); 2013; 17(5):440-5. PubMed ID: 24596533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
    Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
    J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. uPAR and HER2 Genes Are Usually Co-Amplified in Individual Breast Cancer Cells from Blood and Tissues.
    Uhr J
    Breast Care (Basel); 2008; 3(s2):16-19. PubMed ID: 20824009
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumor and vascular targeting of a novel oncolytic measles virus retargeted against the urokinase receptor.
    Jing Y; Tong C; Zhang J; Nakamura T; Iankov I; Russell SJ; Merchan JR
    Cancer Res; 2009 Feb; 69(4):1459-68. PubMed ID: 19208845
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.